Academic Bibliography

Show Sort by

Your filters: cql: jcr.category exact "HEMATOLOGY"

Mark
- conference
- C3
A phase I study in T cell lymphoma patients treated with anti-CD70 simple antibody (TM) ARGX-110

JM Michot, M Maerevoet, P Aftimos, Sylvie Rottey (UGent) , C Rolfo, Fritz Offner (UGent) , L Van Rompaey, M Moshir, H de Haard, K Silence, et al.

(2016) HAEMATOLOGICA. 101(suppl. 1). p.396-396
Mark
- conference
- C3
Oncogenic ZEB2 activation drives sensitivity towards LSD1 inhibition in T-Cell acute lymphoblastic leukemia

Steven Goossens (UGent) , Sofie Peirs (UGent) , Geert Berx (UGent) , Pieter Van Vlierberghe (UGent) and Jody J Haigh

(2016) BLOOD. 128(22).
Mark
- conference
- C3
Cyclin D2 overexpression recapitulates mantle cell lymphoma in mice

Tim Pieters (UGent) , Steven Goossens (UGent) , Sara T'Sas (UGent) , Geert Berx (UGent) , Jody J Haigh and Pieter Van Vlierberghe (UGent)

(2016) BLOOD. 128(22).
Mark
Therapy with low-dose azacitidine for MDS in children and young adults: a retrospective analysis of the EWOG-MDS study group

Annamaria M Cseh, Charlotte M Niemeyer, Ayami Yoshimi, Albert Catala, Michael C Frühwald, Henrik Hasle, Mary M van den Heuvel-Eibrink, Melchior Lauten, Barbara De Moerloose (UGent) , Owen P Smith, et al.

(2016) BRITISH JOURNAL OF HAEMATOLOGY. 172(6). p.930-936
Mark
- misc
Macrophage precursors PLASTed INto alveolar space

Martin Guilliams (UGent) and Bart Lambrecht (UGent)

(2016) BLOOD. 128(24). p.2750-2752
Mark
- conference
- C3
Carfilzomib weekly plus melphalan and prednisone in newly diagnosed elderly multiple myeloma (IFM 2012-03)

X Leleu, G Fouquet, L Karlin, B Kolb, M Tiab, C Araujo, N Meuleman, T de Revel, P Bourquard, P Lenain, et al.

(2016) HAEMATOLOGICA. 101(suppl. 1). p.1-1
Mark
- conference
- C3
Improvement in quality of life and well-being in older patients with treatment-naive (TN) CLL : results from the randomized phase 3 study of ibrutinib (IBR) versus chlorambucil (CLB) (resonate-2™)

P Ghia, A Tedeschi, PM Barr, T Robak, C Owen, O Bairey, P Hillmen, NL Bartlett, J Li, D Simpson, et al.

(2016) HAEMATOLOGICA. 101(suppl. 1). p.55-56
Mark
A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL

Ian W Flinn, Panayiotis Panayiotidis, Boris Afanasyev, Ann Janssens, Sebastian Grosicki, Wojciech Homenda, Lukas Smolej, Kazimierz Kuliczkowski, Michael Doubek, Natalia Domnikova, et al.

(2016) AMERICAN JOURNAL OF HEMATOLOGY. 91(9). p.900-906
Mark
- conference
- C3
Results from the international, randomized phase 3 study of ibrutinib versus chlorambucil in patients 65 years and older with treatment-naive (TN) CLL/SLL (RESONATE-2 (TM))

P Hillmen, A Tedeschi, PM Barr, T Robak, C Owen, P Ghia, O Bairey, NL Bartlett, J Li, D Simpson, et al.

(2016) BRITISH JOURNAL OF HAEMATOLOGY. 173(suppl. 1). p.7-7
Mark
- conference
- C3
A phase I study in T cell lymphoma patients treated with anti-CD70 simple antibody T ARGX-110

JM Michot, K Silence, M Maerevoet, P Aftimos, S Rottey, C Rolfo, Fritz Offner (UGent) , L Van Rompaey, M Moshir, H de Haard, et al.

(2016) HAEMATOLOGICA. 101(suppl. 1). p.105-105

Academic Bibliography

A phase I study in T cell lymphoma patients treated with anti-CD70 simple antibody (TM) ARGX-110

Oncogenic ZEB2 activation drives sensitivity towards LSD1 inhibition in T-Cell acute lymphoblastic leukemia

Cyclin D2 overexpression recapitulates mantle cell lymphoma in mice

Therapy with low-dose azacitidine for MDS in children and young adults: a retrospective analysis of the EWOG-MDS study group

Macrophage precursors PLASTed INto alveolar space

Carfilzomib weekly plus melphalan and prednisone in newly diagnosed elderly multiple myeloma (IFM 2012-03)

Improvement in quality of life and well-being in older patients with treatment-naive (TN) CLL : results from the randomized phase 3 study of ibrutinib (IBR) versus chlorambucil (CLB) (resonate-2™)

A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL

Results from the international, randomized phase 3 study of ibrutinib versus chlorambucil in patients 65 years and older with treatment-naive (TN) CLL/SLL (RESONATE-2 (TM))

A phase I study in T cell lymphoma patients treated with anti-CD70 simple antibody T ARGX-110

Contents

Support

Contact